Comparative Pharmacology
Head-to-head clinical analysis: ISRADIPINE versus VERELAN PM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISRADIPINE versus VERELAN PM.
ISRADIPINE vs VERELAN PM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isradipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into vascular smooth muscle and myocardial cells via L-type calcium channels, leading to vasodilation and reduced peripheral vascular resistance, with minimal negative inotropic effect.
Verapamil is a calcium channel blocker that inhibits the influx of calcium ions across the cardiac and vascular smooth muscle cells, thereby reducing myocardial contractility, sinoatrial and atrioventricular node conduction, and vascular tone.
2.5-10 mg orally twice daily. Initial dose: 2.5 mg twice daily, titrate to 5-10 mg twice daily as needed.
Verelan PM (verapamil hydrochloride) is an extended-release oral capsule administered once daily at bedtime. Typical adult dose for hypertension is 200 mg to 400 mg once daily at bedtime. Initial dose is 200 mg, titrated upward as needed. Maximum recommended dose is 400 mg daily.
None Documented
None Documented
Clinical Note
moderateIsradipine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Isradipine is combined with Etacrynic acid."
Clinical Note
moderateIsradipine + Furosemide
"The risk or severity of adverse effects can be increased when Isradipine is combined with Furosemide."
Clinical Note
moderateIsradipine + Bumetanide
"The risk or severity of adverse effects can be increased when Isradipine is combined with Bumetanide."
Clinical Note
moderateIsradipine + Travoprost
Terminal elimination half-life 8 hours (range 6-12 hours); clinical context: supports twice-daily dosing, requires dose adjustment in hepatic impairment.
Terminal elimination half-life 7.2 ± 1.5 hours after oral administration, prolonged in hepatic impairment (up to 14-16 hours) and elderly; steady-state achieved after 3-4 days.
Renal: 65% (as metabolites, <1% unchanged); Fecal: 35% (biliary elimination); total clearance 1.4 L/min.
Primarily hepatic metabolism (>95%), with 3-4% excreted unchanged in urine; biliary/fecal excretion accounts for <1% of unchanged drug.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker
"Isradipine may increase the hypotensive activities of Travoprost."